Treatment of Plantar Keratosis With Medicinal Plant in Diabetic Patients

NCT03447925 — Phase 2, Completed, 90 participants, Universidade do Vale do Sapucai

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Treatment of Plantar Keratosis With Medicinal Plant in Diabetic Patients: Randomized, Double-Blind and Controlled Clinical Trial

RegistryNCT03447925
StatusCompleted
PhasePhase 2
Study typeInterventional; randomized, parallel, masking: double, treatment
Enrollment90 (Actual)
SponsorUniversidade do Vale do Sapucai (Other)
ConditionsKeratosis Plantaris
InterventionsMedicinal Plant, Salicylate, Vaseline (Drug)
Datesstart 2017-06-01, primary completion 2019-03-01, completion 2020-01-01, first posted 2018-02-27, last updated 2020-11-05
Locations1 site in Brazil

Related Papers Related Patents Related Grants Related Experts
All trials for Keratosis Plantaris All trials of Medicinal Plant All trials of Salicylate

-Summary

This study evaluates the addition of medicinal plant in the treatment of diabetic foot keratosis. Half of participants will receive medicinal plant and other half will receive a placebo.

Expand all sections  ·  Collapse all

+Detailed description

Keratosis in feet or plantar callosity is an injury caused by friction or pressure in certain location of the skin. This is a common problem faced by diabetic patients, which usually cause subcutaneous tissue maceration, which favors bacterial invasion. It is responsible for the development of abscesses and ulcers. Ulcer is the main cause of non-traumatic amputation of the feet in diabetic patients. Treatment with medicinal plants is an ancient practice. Brazil has one of the richest floras in the world. Brazilian Ministry of Health recommends the rational use of medicinal plants and encourage the use of this practice by health professionals.

The medicinal plant used in this study is a keratolytic agent, healing, emollient, bactericide and fungicide. The purpose of this study is evaluate the effectiveness of this medicinal plant in the treatment of keratosis in diabetic patients. This study will be controlled, randomized, comparative with standard drug and double-blind. Will be included in the study 90 adult diabetic patients type 1 or 2, with keratosis, both sexes, but do not show feet ulcerated lesions. Patients will be randomised controlled trials in three groups, with 30 people in each, which will receive topical treatment with medicinal plant (treatment group, TG), salicylate 10% (salicylate group, SG) and vaseline cream (control group, CG). The treatment will be once a day, for 30 consecutive days. Numerical scores will be made of the sites with keratosis and individual areas and global measures in the first, 30th days of treatment. The results obtained will be submitted to statistical comparison. This research will follow the standards set by resolution 466/12 of the National Health Council, the Vale do SapucaĆ­ University, for research with human beings and will be conducted in accordance with the ethical recommendations of the Declaration of Helsinki.

+Arms and interventions

ArmTypeInterventionsDescription
Medicinal Plant X SalicylateExperimentalDrug: Medicinal Plant; Drug: SalicylateTreatment Group (TG) will receive topical treatment with medicinal plant and Salicylate Group (SG) will receive topical treatment with salicylate 10%, both once a day, for 30 consecutive days.
Medicinal Plant X VaselineExperimentalDrug: Medicinal Plant; Drug: VaselineTreatment Group (TG) will receive topical treatment with medicinal plant and Control Group (CG) will receive topical treatment with vaseline cream, both once a day, for 30 consecutive days.
  • Medicinal Plant (Drug), also known as Treatment Group (TG): Medicinal Plant Extract with vaseline cream
  • Salicylate (Drug), also known as Salicylate Group (SG): Salicylate 10% with vaseline cream
  • Vaseline (Drug), also known as Control Group (CG): Vaseline cream

+Outcome measures

Primary outcomes

  • Measures of the sites with plantar keratosis [30 days]: Measures of the sites with plantar keratosis will be made in the first, and 30th days of treatment

+Eligibility

Sex: All, ages: 18 Years to any, accepts healthy volunteers

Inclusion Criteria:

\- diabetic patients type 1 and 2 with plantar keratosis

Exclusion Criteria:

\- feet ulcerated lesions

+Locations (1)

FacilityCityCountryStatus
Beatriz B MartinezPouso Alegre, Minas GeraisBrazil

+Publications

  • Results publication: Arosi I, Hiner G, Rajbhandari S. Pathogenesis and Treatment of Callus in the Diabetic Foot. Curr Diabetes Rev. 2016;12(3):179-83. doi: 10.2174/1573399811666150609160219. PMID 26054651
  • Results publication: Caravaggi C, Sganzaroli A, Galenda P, Bassetti M, Ferraresi R, Gabrielli L. The management of the infected diabetic foot. Curr Diabetes Rev. 2013 Jan 1;9(1):7-24. PMID 22934545